Mechanisms of bone destruction in multiple myeloma
- PMID: 28940410
- DOI: 10.1111/ecc.12761
Mechanisms of bone destruction in multiple myeloma
Abstract
Osteolytic bone disease is a frequent complication of multiple myeloma, resulting in skeletal complications that are a significant cause of morbidity and mortality. It is the result of an increased activity of osteoclasts, which is not followed by reactive bone formation by osteoblasts. Recent studies have revealed novel molecules and pathways that are implicated in osteoclast activation and osteoblast inhibition. Among them, the most important include the receptor activator of nuclear factor-kappa B ligand/osteoprotegerin pathway, the macrophage inflammatory proteins and the activin-A that play a crucial role in osteoclast stimulation in myeloma, while the wingless-type (Wnt) signalling inhibitors (sclerostin and dickkopf-1) along with the growth factor independence-1 are considered the most important factors for the osteoblast dysfunction of myeloma patients. Finally, the role of osteocytes, which is the key cell for normal bone remodelling, has also revealed during the last years through their interaction with myeloma cells that leads to their apoptosis and the release of RANKL and sclerostin maintaining bone loss in these patients. This review focuses on the latest available data for the mechanisms of bone destruction in multiple myeloma.
Keywords: Wnt pathway; bone disease; chemokine (C-C motif) ligand 3; growth factor independence-1; multiple myeloma; osteocyte; receptor activator of nuclear factor-kB ligand (RANKL).
© 2017 John Wiley & Sons Ltd.
Similar articles
-
Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.Cancer Res. 2016 Mar 1;76(5):1089-100. doi: 10.1158/0008-5472.CAN-15-1703. Epub 2016 Feb 1. Cancer Res. 2016. PMID: 26833121 Free PMC article.
-
Role of the bone marrow microenvironment in multiple myeloma.J Bone Miner Res. 2002 Nov;17(11):1921-5. doi: 10.1359/jbmr.2002.17.11.1921. J Bone Miner Res. 2002. PMID: 12412796
-
Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.Blood. 2008 Jul 1;112(1):196-207. doi: 10.1182/blood-2008-01-132134. Epub 2008 Feb 27. Blood. 2008. PMID: 18305214 Free PMC article.
-
Update on the pathogenesis of osteolysis in multiple myeloma patients.Acta Biomed. 2004 Dec;75(3):143-52. Acta Biomed. 2004. PMID: 15796087 Review.
-
Pathogenesis and management of myeloma bone disease.Expert Rev Hematol. 2009 Aug;2(4):385-98. doi: 10.1586/ehm.09.36. Expert Rev Hematol. 2009. PMID: 21082944 Review.
Cited by
-
Final analysis of a phase 1/2b study of ibrutinib combined with carfilzomib/dexamethasone in patients with relapsed/refractory multiple myeloma.Hematol Oncol. 2020 Aug;38(3):353-362. doi: 10.1002/hon.2723. Epub 2020 Mar 11. Hematol Oncol. 2020. PMID: 32053229 Free PMC article. Clinical Trial.
-
A novel proteomic signature of osteoclast differentiation unveils the deubiquitinase UCHL1 as a necessary osteoclastogenic driver.Sci Rep. 2024 Mar 27;14(1):7290. doi: 10.1038/s41598-024-57898-y. Sci Rep. 2024. PMID: 38538704 Free PMC article.
-
Multiple Myeloma Bone Disease: Implication of MicroRNAs in Its Molecular Background.Int J Mol Sci. 2021 Feb 27;22(5):2375. doi: 10.3390/ijms22052375. Int J Mol Sci. 2021. PMID: 33673480 Free PMC article. Review.
-
Using Prognosis-Related Gene Expression Signature and Connectivity Map for Personalized Drug Repositioning in Multiple Myeloma.Med Sci Monit. 2019 May 2;25:3247-3255. doi: 10.12659/MSM.913970. Med Sci Monit. 2019. PMID: 31048671 Free PMC article.
-
Myeloma Bone Disease: The Osteoblast in the Spotlight.J Clin Med. 2021 Sep 2;10(17):3973. doi: 10.3390/jcm10173973. J Clin Med. 2021. PMID: 34501423 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical